Pyxis Oncology Inc (PYXS)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$3.89+8.96%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · PYXS
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | |
|---|---|---|---|---|---|---|---|
| Revenues | |||||||
| Revenues | — | 13.9 | 16.1 | — | — | — | — |
| Total Revenues | — | 13.9 | 16.1 | — | — | — | — |
| Cost of Revenues | — | 2.4 | 0.5 | — | — | — | — |
| Operating Expenses & Income | |||||||
| R&D Expenses | 75.6 | 73.7 | 58.7 | 49.6 | 86.1 | 51.1 | 9.0 |
| Operating Income | (92.1) | (84.4) | (89.5) | (82.2) | (123.5) | (69.7) | (12.9) |
| Earnings from Continuing Operations | |||||||
| Interest & Investment Income | 0.7 | 0.7 | 0.9 | 1.8 | 2.8 | 0.0 | 0.1 |
| Other Non-Operating Income / Expenses | 4.5 | 6.2 | 10.0 | 8.4 | 2.8 | (6.0) | 0.1 |
| EBT, Incl. Unusual Items | — | (78.2) | (79.5) | (73.8) | — | — | — |
| Income Tax Expense | — | 1.4 | (2.2) | — | — | — | — |
| Net Income | |||||||
| Net Income | (88.7) | (79.6) | (77.3) | (73.8) | (120.7) | (76.0) | (12.8) |
| Per Share | |||||||
| Basic EPS | (1.39) | (1.28) | (1.32) | (1.85) | (3.65) | (8.95) | — |
| Diluted EPS | (1.39) | (1.28) | (1.32) | (1.85) | (3.65) | (8.95) | — |
| Basic Weighted Avg Shares | 64.0 | 62.1 | 58.4 | 39.9 | 33.0 | 8.5 | — |
| Diluted Weighted Avg Shares | 64.0 | 62.1 | 58.4 | 39.9 | 33.0 | 8.5 | — |
| Supplemental | |||||||
| EBITDA | — | (79.9) | (86.5) | (80.3) | (122.8) | (69.1) | (12.4) |
| EBIT | (92.1) | (84.4) | (89.5) | (82.2) | (123.5) | (69.7) | (12.9) |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.